Form 4: NeoGenomics Director John P. Kenny Reports Equity Changes

Director John P. Kenny acquired 5,893 shares of NeoGenomics common stock through the vesting of restricted stock units.

Summary

• Director John P. Kenny exercised and acquired 5,893 shares of common stock via the vesting of restricted stock units (RSUs) on June 1, 2026.
• The reporting person was granted 11,069 stock options with an exercise price of $10.52, exercisable starting June 1, 2027.
• The reporting person was granted 15,970 restricted stock units on June 1, 2026, vesting on June 1, 2027.
• Following these transactions, the director holds 5,893 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard director compensation and does not signal a change in company strategy or financial health.

Positives

• Director alignment with shareholder interests through increased equity ownership.
• Standard equity-based compensation structure for board members.

Negatives

• None identified.

Risks

• Market price volatility affecting the value of granted stock options and RSUs.
• Future dilution of existing shareholders upon the exercise of options and vesting of RSUs.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director equity transactions.

Industry Context

StockSavvy.ai notes that this filing represents routine director compensation and equity alignment, which is standard practice for publicly traded biotechnology and diagnostic companies to ensure board members maintain a vested interest in long-term corporate performance.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is consistent with standard corporate governance practices in the healthcare and diagnostics sector.
• The vesting schedule of one year for director equity is typical for mid-cap growth companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to future issuance of shares upon option exercise and RSU vesting.

Next Steps

• Vesting of granted stock options on June 1, 2027.
• Vesting of granted restricted stock units on June 1, 2027.

Key Dates

Keywords

NeoGenomics, NEO, Form 4, Insider Trading, Director Compensation, Equity Grant